
Robert P Giugliano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9149405/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	27.0	4,215
2	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	27.0	4,179
3	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, The, 2014, 383, 955-962.	13.7	3,942
4	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 372, 2387-2397.	27.0	3,337
5	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1500-1509.	27.0	1,352
6	TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. Circulation, 2000, 102, 2031-2037.	1.6	1,302
7	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA - Journal of the American Medical Association, 2016, 316, 1289.	7.4	974
8	Abciximab Facilitates the Rate and Extent of Thrombolysis. Circulation, 1999, 99, 2720-2732.	1.6	661
9	Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes. Circulation, 2005, 111, 2042-2049.	1.6	613
10	Variation in <i>PCSK9</i> and <i>HMGCR</i> and Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine, 2016, 375, 2144-2153.	27.0	596
11	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation, 2018, 137, 338-350.	1.6	559
12	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
13	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, The, 2017, 390, 1962-1971.	13.7	487
14	Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. New England Journal of Medicine, 2009, 360, 2176-2190.	27.0	459
15	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 941-950.	11.4	452
16	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48). American Heart Journal, 2010, 160, 635-641.e2.	2.7	439
17	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet, The, 2012, 380, 2007-2017.	13.7	379
18	Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 2017, 377, 633-643.	27.0	366

#	Article	IF	CITATIONS
19	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2288-2295.	13.7	335
20	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288.	2.8	316
21	TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction. Circulation, 1998, 98, 2805-2814.	1.6	307
22	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. Circulation, 2018, 137, 1571-1582.	1.6	304
23	The P-Glycoprotein Transport System and Cardiovascular Drugs. Journal of the American College of Cardiology, 2013, 61, 2495-2502.	2.8	297
24	Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQqO outcomes in patients with acute coronary syndromes. American Heart Journal, 2008, 156, 826-832.	0 0 rgBT / 2.7	Overlock 101 280
25	Antibiotic Treatment of <i>Chlamydia pneumoniae</i> after Acute Coronary Syndrome. New England Journal of Medicine, 2005, 352, 1646-1654.	27.0	278
26	Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction. Circulation, 2000, 101, 239-243.	1.6	267
27	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation, 2015, 132, 1224-1233.	1.6	267
28	Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. Journal of the American College of Cardiology, 2003, 42, 1535-1543.	2.8	247
29	A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet, The, 2001, 358, 1571-1575.	13.7	245
30	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation, 2016, 134, 24-36.	1.6	234
31	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of Clinical Lipidology, 2016, 10, 472-489.	1.5	219
32	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	215
33	St-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. American Journal of Cardiology, 2000, 85, 299-304.	1.6	212
34	Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation, 2014, 129, 234-243.	1.6	204
35	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. Circulation, 2018, 138, 756-766.	1.6	200
36	Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation, 2018, 138, 131-140.	1.6	194

#	Article	IF	CITATIONS
37	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Journal of Lipid Research, 2016, 57, 1086-1096.	4.2	180
38	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. European Heart Journal, 2014, 35, 1457-1465.	2.2	174
39	Reduction in Total Cardiovascular Events WithÂEzetimibe/Simvastatin Post-Acute Coronary Syndrome. Journal of the American College of Cardiology, 2016, 67, 353-361.	2.8	173
40	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes. Circulation, 2019, 140, 1308-1317.	1.6	172
41	Nonvitamin K Anticoagulant Agents inÂPatients With Advanced Chronic KidneyÂDisease or on Dialysis With AF. Journal of the American College of Cardiology, 2016, 67, 2888-2899.	2.8	171
42	Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Circulation, 2004, 109, 580-586.	1.6	169
43	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643.	13.7	167
44	Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality. Circulation, 2011, 123, 2681-2689.	1.6	164
45	AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy. Circulation, 2013, 128, 962-969.	1.6	161
46	Meta-analysis of corticosteroid treatment in acute myocardial infarction. American Journal of Cardiology, 2003, 91, 1055-1059.	1.6	160
47	Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. Journal of the American College of Cardiology, 2003, 42, 7-16.	2.8	160
48	Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal, 2016, 173, 94-101.	2.7	158
49	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. JAMA Cardiology, 2018, 3, 823.	6.1	158
50	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology, 2017, 69, 911-921.	2.8	157
51	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. Journal of the American College of Cardiology, 2015, 65, 2638-2651.	2.8	156
52	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2280-2287.	13.7	153
53	U-Shaped Relationship of Blood Glucose With Adverse Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 178-180.	2.8	152
54	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. JAMA Cardiology, 2017, 2, 547.	6.1	144

#	Article	IF	CITATIONS
55	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. Circulation, 2020, 141, 616-623.	1.6	143
56	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	139
57	Evaluation of the time saved byprehospital initiation of reteplase forST-elevation myocardial infarction. Journal of the American College of Cardiology, 2002, 40, 71-77.	2.8	138
58	Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. Journal of the American College of Cardiology, 1999, 34, 974-982.	2.8	137
59	Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. JAMA Cardiology, 2017, 2, 598.	6.1	137
60	Novel biomarkers in cardiovascular disease: Update 2010. American Heart Journal, 2010, 160, 583-594.	2.7	136
61	Edoxaban Versus Warfarin in AtrialÂFibrillation Patients at Risk of Falling. Journal of the American College of Cardiology, 2016, 68, 1169-1178.	2.8	133
62	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation, 2017, 135, 1273-1275.	1.6	133
63	Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thrombosis and Haemostasis, 2012, 107, 925-934.	3.4	132
64	Updates on Acute Coronary Syndrome. JAMA Cardiology, 2016, 1, 718.	6.1	127
65	Oral Anticoagulation in Patients WithÂLiver Disease. Journal of the American College of Cardiology, 2018, 71, 2162-2175.	2.8	127
66	Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. European Heart Journal, 2004, 25, 1998-2005.	2.2	124
67	Acute coronary syndromes. Lancet, The, 2022, 399, 1347-1358.	13.7	122
68	Anticoagulation Strategies in PatientsÂWith Cancer. Journal of the American College of Cardiology, 2019, 73, 1336-1349.	2.8	121
69	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study. Journal of the American College of Cardiology, 1999, 33, 1879-1885.	2.8	119
70	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1069.	6.1	119
71	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
72	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. European Heart Journal, 2014, 35, 2249-2259.	2.2	115

#	Article	IF	CITATIONS
73	Efficacy and Safety of Evolocumab inÂChronic Kidney Disease in the FOURIERÂTrial. Journal of the American College of Cardiology, 2019, 73, 2961-2970.	2.8	115
74	Thiazolidinedione Drugs and Cardiovascular Risks. Circulation, 2010, 121, 1868-1877.	1.6	113
75	Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina. Archives of Internal Medicine, 1998, 158, 1113.	3.8	112
76	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal, 2016, 37, 1296.1-1303.	2.2	112
77	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGEÂAF-TIMI 48 Trial. Journal of the American College of Cardiology, 2017, 69, 1372-1382.	2.8	111
78	Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology, 2022, 7, 250.	6.1	108
79	Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2018, 7, e008987.	3.7	105
80	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. JAMA Cardiology, 2018, 3, 749.	6.1	105
81	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
82	Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. Journal of the American College of Cardiology, 2017, 69, 1363-1371.	2.8	102
83	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq1 1	0. 7.8 4314	1 rgB∑ /Overla
84	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke, 2020, 51, 1546-1554.	2.0	102
85	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 2132-2146.	2.8	101
86	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation, 2019, 139, 760-771.	1.6	99
87	Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation, 2016, 134, 248-261.	1.6	98
88	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 934-943.	11.4	96
89	Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction. Journal of the American College of Cardiology, 2003, 41, 1251-1260.	2.8	93
90	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. American Heart Journal, 2014, 168, 205-212.e1.	2.7	93

#	Article	IF	CITATIONS
91	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AFâ€TIMI48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	93
92	Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. American Heart Journal, 2002, 144, 1003-1011.	2.7	92
93	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 1340-1360.	2.8	92
94	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. JAMA Cardiology, 2017, 2, 1385.	6.1	89
95	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2019, 40, 1541-1550.	2.2	88
96	Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non–ST-segment elevation acute coronary syndrome. American Heart Journal, 2013, 165, 918-925.e2.	2.7	87
	The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY) Tj E	TQq1 1 0.7	'84314 rgBT
97	front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale. American Heart Iournal. 2005. 149. 994-1002.	2.7	85
98	Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2003, 289, 331.	7.4	84
99	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke, 2016, 47, 2075-2082.	2.0	83
100	Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation – An ENGAGE AF-TIMI 48 Subanalysis –. Circulation Journal, 2016, 80, 860-869.	1.6	83
101	An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. American Heart Journal, 2010, 159, 705-709.	2.7	82
102	Lipoprotein(a) and its Significance in Cardiovascular Disease. JAMA Cardiology, 2022, 7, 760.	6.1	82
103	Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4A simple index that predicts mortality in ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 783-789.	2.8	81
104	Thiazolidinedione Drugs and Cardiovascular Risks. Journal of the American College of Cardiology, 2010, 55, 1885-1894.	2.8	81
105	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. JAMA Cardiology, 2019, 4, 846.	6.1	81
106	Angiographic and Clinical Outcomes Among Patients With Acute Coronary Syndromes Presenting With Isolated Anterior ST-Segment Depression. JACC: Cardiovascular Interventions, 2010, 3, 806-811.	2.9	79
107	Comparison of long-term mortality across the spectrum of acute coronary syndromes. American Heart Journal, 2006, 151, 1065-1071.	2.7	77
108	Digoxin: Clinical Highlights. Critical Pathways in Cardiology, 2011, 10, 93-98.	0.5	77

#	Article	IF	CITATIONS
109	Selecting the Best Reperfusion Strategy in ST-Elevation Myocardial Infarction. Circulation, 2003, 108, 2828-2830.	1.6	76
110	Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes. Circulation, 2012, 126, 41-49.	1.6	74
111	Prognostic Performance of a High-Sensitivity Cardiac Troponin I Assay in Patients with Non–ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2014, 60, 158-164.	3.2	74
112	High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction. Circulation, 2000, 101, 2690-2695.	1.6	73
113	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from <scp>ENGAGE AF‶IMI</scp> 48. European Journal of Heart Failure, 2016, 18, 1153-1161.	7.1	73
114	Recombinant Nematode Anticoagulant Protein c2 in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 49, 2398-2407.	2.8	72
115	Rationale and design of the EMBRACE STEINI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. American Heart	2.7	72
116	Journal, 2013, 165, 509-514.67. Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. American Heart Journal, 2004, 148, 336-340.	2.7	71
117	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. European Heart Journal, 2016, 37, 3576-3584.	2.2	71
118	Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. American Heart Journal, 2001, 141, 742-750.	2.7	69
119	Determinants of coronary blood flow after thrombolytic administration. Journal of the American College of Cardiology, 1999, 34, 1403-1412.	2.8	67
120	Novel Oral Anticoagulants in Atrial Fibrillation: A Metaâ€analysis of Large, Randomized, Controlled Trials vs Warfarin. Clinical Cardiology, 2013, 36, 61-67.	1.8	67
121	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2019, 40, 1518-1527.	2.2	67
122	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. JAMA Cardiology, 2019, 4, 613.	6.1	66
123	Implications of Upstream Glycoprotein IIb/IIIa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/Non–ST-Elevation Myocardial Infarction. Circulation, 2004, 109, 874-880.	1.6	65
124	Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. Journal of the American College of Cardiology, 2008, 52, 914-920.	2.8	64
125	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 999.	6.1	64
126	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	6.1	63

127Canning and the Lowering LDC Cholesterol With Evologiants by Journal of the American College of Canning and Canner and Can	#	Article	IF	CITATIONS
128 Thrombaembolism, Circulation, 2020, 141, 1600-1607. 1.0 61 129 The Role of Clopidogrel in Early and Sustained Arterial Patency After Florinolysis for ST-Segment. 2.8 60 130 Current and new oral antithrombotics in non-valuular atrial fibrillation: a network meta-analysis of 794E808 patients. Heart, 2014, 100, 396-405. 2.9 58 131 Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial/Fibrillation and Heart Falure. 4.1 58 132 Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial/Fibrillation and Heart Falure. 4.1 58 132 Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial/Fibrillation and Heart Falure. 4.1 58 132 Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial/Fibrillation and Heart Falure. 4.1 58 133 anglographells. betruck econorum and revel desace cheby automs from \$7,101 patients. European 1.0 57 134 DL-cholestorol lowering with evolocumab, and outcomes according to age and sex in patients with an endocumation acute cardioage.2020, 5.95.2 1.8 54 134 Efficacy of Evolocumab on Cardioasacular Outcomes in Patients With Recent Myocardial Infarction. 6.1 56 134 Efficacy of Evolocumab on Cardioasacular Outcome	127	Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 2020, 75, 2283-2293.	2.8	62
129 Elevation Myocardial Infarction, Journal of the American College of Cardiology, 2006, 48, 37-42. 2.3 00 130 Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 2.9 58 131 Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial/Fibrillation and Heart Failure. 4.1 58 132 Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial/Fibrillation and Heart Failure. 4.1 58 132 Excert Failure, 2016, 4, 870-880. 1.5 58 134 Excert Failure, 2016, 4, 870-880. 1.5 58 135 Coluctomes among function acute coronary syndromes patients with no 57 134 Elevation Mathematic Coronary attery disease: observations from 37,101 patients. European 1.0 57 134 Diccholestrol lowering with evolocumab, and outcomes according to age and sex in patients in the 1.8 57 135 Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. 6.1 56 136 Atrial Fibrillation, Type 2 Diabetes, and Non&E"Vitamin K Antagonist Oral Anticoagulants. JAMA 6.1 56 137 multicenter aturb to assess the effect of evolocurnab on cogolition in patients with clinicaly aturbat	128	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 2020, 141, 1600-1607.	1.6	61
130 7986808 patients. Heart, 2014, 100, 396-405. 2.9 58 131 Efficacy and Safety of Novel Oral Anticoagulants in Patients With AtrialAFIbrillation and Heart Failure. 4.1 58 131 Efficacy and Safety of Novel Oral Anticoagulants in Patients With AtrialAFIbrillation and Heart Failure. 4.1 58 132 Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the 1.8 58 133 antiographically Obstructive coronary syndromes patients with no 1.0 57 134 Dutcomes among non-ST-segment elevation acute coronary syndromes patients. European 1.0 57 134 LDL-cholesteriol lowering with evolocumab, and outcomes according to age and sex in patients in the 1.8 57 135 Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. 6.1 56 136 Arrial Fibrillation, Type 2 Diabetes, and Nonáč Vitamin K Antagonist Oral Anticoagulants. JAMA 6.1 55 137 Design and rationale of the cscp>EBBINCHAUS/Jscp> trial: A phase 3, doubleáčbilnd, placeboáčcontrolled, multicenter study to assess the effect of evolocumab on cognitive function in patients with chically vido patients enrolled in the escop EDBINCHAUS/Jscp> trial: A phase 3, doubleáčbilnd, placeboáčcontrolled, multicenter andy the asses of Edivers of Evone Setos trial. Clinical Cardi	129		2.8	60
133 JACC: Heart Failure, 2016, 4, 870-880. 41 53 132 Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGACE AF-TIMI 48 Trial. American Journal of Medicine, 2016, 129, 850-857.e2. 1.5 58 133 Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary attem disease: observations from 37,101 patients. European 1.0 57 134 LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. European Journal of Preventive Cardiology, 2021, 28, 805-812. 1.8 57 135 Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JMAA Cardiology, 2020, 5, 952. 6.1 56 136 Artial Fibrillation, Type 2 Diabetes, and Non&C*Vitamin K Antagonist Oral Anticoagulants. JAMA Cardiology, 2017, 2, 442. 6.1 55 137 multicents ruly to asses the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidatiovering therapyde? A cognitive study of patients arguestoFDER/RER/Csot Tid. Clinical Cardiology, 2017, 40, 59-56 54 138 Outcomes of Women Compared With Men After Non&C*ST Segment Elevation AcuteÅCoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022. 2.8 53 138 Outcomes of Women Compared	130		2.9	58
132 ENGAGE AF-TIMI 48 Trial. American Journal of Medicine, 2016, 129, 850-857.e2. 1.3 1.3 58 133 Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary attery disease: observations from 37,101 patients. European 1.0 57 134 EDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. European Journal of Preventive Cardiology, 2021, 28, 805-812. 1.8 57 135 Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952. 6.1 56 136 Atrial Fibrillation, Type 2 Diabetes, and Nonáč ^{ev} Vitamin K Antagonist Oral Anticoagulants. JAMA Cardiology, 2017, 2, 442. 6.1 55 137 Design and rationale of the <scp>EBBINCHAUS 1.8 54 138 Journal of the American College of Cardiology, 2017, 40, 59-65. 1.8 54 139 Outcomes of Women Compared With Men After Nonáč^{ev}ST-Segment Elevation AcuteÁCoronary Syndromes. 2.8 54 140 Sudden Cardia Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFãeCIMI 48 Trial. 3.7 53 140 Sudden Cardia Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFãeCIMI 48 Trial. 3.7 53 141</scp>	131		4.1	58
133 anglographically obstructive coronary attery disease: observations from 37,101 patients. European 1.0 57 134 FOURRER Trial. European Journal of Preventive Cardiology, 2021, 28, 805-812. 1.8 57 135 Efficacy of Evolocumab, and outcomes according to age and sex in patients in the FOURRER Trial. European Journal of Preventive Cardiology, 2021, 28, 805-812. 6.1 56 136 Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. 6.1 56 136 Atrial Fibrillation, Type 2 Diabetes, and Nonãé Vitamin K Antagonist Oral Anticoagulants. JAMA 6.1 55 137 multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidaEowering therapy&C A cognitive study of patients ecopy FOIMER/secops 161. Clinical Cardiology, 2017, 9, 955. 1.8 54 138 Outcomes of Women Compared With Men After Nonãe ST Segment Elevation AcuteAcoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022. 2.8 53 139 Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984. 3.7 53 140 Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFãeCTIMI 48 Trial. Journal of the American Heart Association, 2016, 5, . 1.8 53 </td <td>132</td> <td></td> <td>1.5</td> <td>58</td>	132		1.5	58
134 FOURIER Trial. European Journal of Preventive Cardiology, 2021, 28, 805-812. 1.8 57 135 Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. 6.1 56 136 Atrial Fibrillation, Type 2 Diabetes, and NonêC"Vitamin K Antagonist Oral Anticoagulants. JAMA 6.1 55 136 Atrial Fibrillation, Type 2 Diabetes, and NonêC"Vitamin K Antagonist Oral Anticoagulants. JAMA 6.1 55 137 multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidâCowering therapyâC"A cognitive study of patients enrolled in the <scp>FOURIER/scp> trial. Clinical Cardiology, 2017, 40, 594 54 138 Outcomes of Women Compared With Men After Non8C"ST-Segment Elevation AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984. 53 140 Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, . 53 141 Cardiology, 2017, Cardiology, 2016, 5, . 1.8 53 142 Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Guigiliano was supported by grant HL-03533 and Dr. Guigiliano was supported by grant HL-03532 and Dr. Guigiliano was supported by grant HL-03</scp>	133	angiographically obstructive coronary artery disease: observations from 37,101 patients. European	1.0	57
153JAMA Cardiology, 2020, 5, 952.6.156136Atrial Fibrillation, Type 2 Diabetes, and Nonâ€"Vitamin K Antagonist Oral Anticoagulants. JAMA Cardiology, 2017, 2, 442.6.155137Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, doubleâ€blind, placeboâ€controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidâ€Gwering therapyã€"A cognitive study of patients enrolled in the <scp>FOURER1.854137Outcomes of Women Compared With Men After Nonã€"ST-Segment Elevation AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022.2.854138Outcomes of Women Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984.2.853140Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .3.753141Cardioversion of Atrial Fibrillation in <scp>ENGAGE AFâ€TIMI48. Clinical Cardiology, 2016, 39, 345-346.1.853142Litable Angina Pectoris 11Dr. Camargo was supported by grant HL-035333 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland. American Journal of Cardiology, 199, 81, 1182-1186.51143The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270, 1.751</scp></scp>	134		1.8	57
136 Cardiology, 2017, 2, 442. 6.1 55 137 Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, doubleå€blind, placeboå€controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidå€lowering therapyå€"A cognitive study of patients enrolled in the <scp>FOURER</scp> trial: Clinical Cardiology. 2017, 40, 59-65. 1.8 54 138 Outcomes of Women Compared With Men After Nonâ€"ST-Segment Elevation AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022. 2.8 54 139 Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984. 2.8 53 140 Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, . 3.7 53 141 Cardioversion of Atrial Fibrillation in <scp>ENGAGE AFâ€TIMI 48. Clinical Cardiology, 2016, 39, 1.8 53 142 Liectrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Glugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland American lournal of Cardiology, 1998, 81, 1182-1186. 51 142 The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification an</scp>	135		6.1	56
137multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidaGowering therapy&C*A cognitive study of patients enrolled in the <scop 2017.="" 40.="" 59-65.<="" cardiology.="" clinical="" fourier<="" scop="" th="" trial.="">1.854138Outcomes of Women Compared With Men After Non&C*ST-Segment Elevation Acute&Coronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022.2.854139Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984.2.853140Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF&FIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .3.753141Cardioversion of Atrial Fibrillation in <scp>ENGAGE AF&FIMI48. Clinical Cardiology, 2016, 39, 345-346.1.853142Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-03575 from the National Institutes of Health, Bethesda, Maryland. American Journal of Cardiology, 1998, 81, 1182-1186.1.651143The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270, 1.71.751</br></br></scp></scop>	136		6.1	55
138 Journal of the American College of Cardiology, 2019, 74, 3013-3022. 2.8 54 139 Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984. 2.8 53 140 Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, . 3.7 53 141 Cardioversion of Atrial Fibrillation in <scp>ENGAGE AFâ€TIMI Scop 48. Clinical Cardiology, 2016, 39, 345-346. 1.8 53 142 Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland American Journal of Cardiology, 1998, 81, 1182-1186. 51 143 The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270, 1.7 51</scp>	137	multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidâ€lowering therapy—A cognitive	1.8	54
13954, 969-984.2.853140Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .3.753141Cardioversion of Atrial Fibrillation in <scp>ENGAGE AFâ€TIMI</scp> 48. Clinical Cardiology, 2016, 39, 345-346.1.853142Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland American Journal of Cardiology, 1998, 81, 1182-1186.1.651143The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270,1.751	138	Outcomes of Women Compared With Men After Non–ST-Segment Elevation AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022.	2.8	54
140Journal of the American Heart Association, 2016, 5, .3.753141Cardioversion of Atrial Fibrillation in <scp>ENGAGE AFâ€TIMI</scp> 48. Clinical Cardiology, 2016, 39, 345-346.1.853142Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland American Journal of Cardiology, 1998, 81, 1182-1186.1.651143The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270,1.751	139	Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984.	2.8	53
141345-346.1.853142Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland American Journal of Cardiology, 1998, 81, 1182-1186.1.651143The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270,1.751	140		3.7	53
142Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland American1.651142Journal of Cardiology, 1998, 81, 1182-1186.51The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270,1.751	141		1.8	53
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a 143 strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270, 1.7 51	142	Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland American	1.6	51
	143	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270,	1.7	51

Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the) Tj ETQq0 0 0 rgBI $_{.6}^{-0}$ Overlock 10 Tf 50

#	Article	IF	CITATIONS
145	Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment–Elevation Myocardial Infarction. Circulation, 2004, 110, 679-684.	1.6	50
146	AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program–Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients. Journal of the American College of Cardiology, 2014, 63, 430-433.	2.8	50
147	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. JAMA Cardiology, 2021, 6, 139.	6.1	50
148	Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. American Journal of Cardiology, 2004, 93, 1362-1367.	1.6	49
149	Neural Network Assessment of Perioperative Cardiac Risk in Vascular Surgery Patients. Medical Decision Making, 1998, 18, 70-75.	2.4	48
150	Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. American Journal of Cardiology, 2000, 86, 1235-1237.	1.6	48
151	Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. American Journal of Cardiology, 2001, 88, 353-358.	1.6	48
152	Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4. Journal of the American College of Cardiology, 2004, 44, 783-789.	2.8	48
153	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationâ€. European Heart Journal, 2015, 36, 1470-1477.	2.2	47
154	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	2.0	46
155	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
156	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. European Heart Journal, 2019, 40, 1492-1500.	2.2	45
157	Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab. JAMA Cardiology, 2019, 4, 59.	6.1	45
158	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. European Journal of Heart Failure, 2019, 21, 1571-1579.	7.1	44
159	Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 980-987.	2.8	43
160	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVEâ€IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association, 2017, 6, .	3.7	43
161	Efficacy of a Nasal Spray Containing lota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. International Journal of General Medicine, 2021, Volume 14, 6277-6286.	1.8	43
162	Distance from the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial Infarction and its Implications Regarding the Potential Prevention of Proximal Plaque Rupture. Journal of Thrombosis and Thrombolysis, 2003, 15, 189-196.	2.1	42

#	Article	IF	CITATIONS
163	Patterns and predictors of lipidâ€lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large <scp>US</scp> managedâ€care population. Clinical Cardiology, 2017, 40, 155-162.	1.8	41
164	Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non–ST-Elevation myocardial infarction. American Journal of Cardiology, 2004, 93, 1218-1222.	1.6	40
165	The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 906-919.	2.8	40
166	Prior Aspirin Use and Outcomes in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 56, 1376-1385.	2.8	39
167	Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome. Circulation, 2011, 123, 722-730.	1.6	39
168	Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 205-213.	2.2	39
169	Cardiac Troponin After Percutaneous CoronaryÂIntervention and 1-YearÂMortality inÂNon–ST-Segment Elevation Acute Coronary SyndromeÂUsingÂSystematic Evaluation ofÂBiomarkerÂTrends. Journal of the American College of Cardiology, 2013, 62, 242-251.	2.8	39
170	Transition of Patients From Blinded StudyÂDrug to Open-Label Anticoagulation. Journal of the American College of Cardiology, 2014, 64, 576-584.	2.8	39
171	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2021, 144, 1845-1855.	1.6	39
172	Association of Unstable Angina Guideline Care With Improved Survival. Archives of Internal Medicine, 2000, 160, 1775.	3.8	37
173	Design and Rationale of the LAPLACEâ€TIMI 57 Trial: A Phase II, Doubleâ€Blind, Placeboâ€Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy. Clinical Cardiology, 2012, 35, 385-391.	1.8	37
174	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. European Heart Journal, 2017, 38, ehw565.	2.2	37
175	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With PriorÂMyocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1660-1671.	2.8	36
176	Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. European Heart Journal, 2010, 31, 2103-2110.	2.2	35
177	Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin – Insights From the ENGAGE AF-TIMI 48 Trial –. Circulation Journal, 2015, 79, 2560-2567.	1.6	35
178	Edoxaban Versus Warfarin in PatientsÂWith Atrial Fibrillation and History of Liver Disease. Journal of the American College of Cardiology, 2019, 74, 179-189.	2.8	35
179	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Research Reviews, 2019, 49, 115-124.	10.9	34
180	Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 448-458.	2.2	33

#	Article	IF	CITATIONS
181	Gastrointestinal Bleeding With Edoxaban Versus Warfarin. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e003998.	2.2	33
182	Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. American Journal of Cardiology, 2004, 94, 1406-1410.	1.6	32
183	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation, 2018, 138, 1963-1973.	1.6	32
184	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. Journal of the American College of Cardiology, 2019, 74, 1057-1068.	2.8	32
185	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
186	Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non–ST-elevation myocardial infarction. American Journal of Cardiology, 2003, 92, 1155-1159.	1.6	31
187	Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. European Heart Journal, 2004, 25, 1702-1710.	2.2	31
188	Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (A Meta-Analysis of a Decade of Trials). Journal of Thrombosis and Thrombolysis, 2006, 21, 119-129.	2.1	31
189	Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. American Heart Journal, 2009, 157, 673-679.e1.	2.7	31
190	The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2010, 56, 2126-2138.	2.8	31
191	Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention–Related Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 2296-2304.	2.8	31
192	Evolocumab in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 785-788.	27.0	31
193	Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2005, 45, 321-323.	2.8	30
194	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 357-367.	2.2	30
195	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AFâ€∏IMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	3.7	30
196	Non–Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves. Circulation, 2018, 138, 1356-1365.	1.6	30
197	A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. Journal of Thrombosis and Thrombolysis, 2000, 9, 175-180.	2.1	29
198	Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. American Heart Journal, 2002, 143, 966-970.	2.7	29

#	Article	IF	CITATIONS
199	The Prognostic Significance of Cardiac Structure andÂFunction in Atrial Fibrillation: The ENGAGE AF–TIMI 48 Echocardiographic Substudy. Journal of the American Society of Echocardiography, 2016, 29, 537-544.	2.8	29
200	Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the American College of Cardiology, 2020, 75, 289-300.	2.8	29
201	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 77, 1197-1207.	2.8	29
202	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European Heart Journal, 2018, 39, 3810-3820.	2.2	28
203	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2021, 42, 1698-1706.	2.2	27
204	Effects of tirofiban plus heparin versus heparin alone on troponin i levels in patients with acute coronary syndromes. American Journal of Cardiology, 2000, 86, 713-717.	1.6	26
205	First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. American Heart Journal, 2000, 140, 81-92.	2.7	26
206	Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. American Heart Journal, 2000, 140, 373-378.	2.7	26
207	Association of Epicardial and Tissue-Level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction. Journal of Thrombosis and Thrombolysis, 2004, 17, 177-184.	2.1	26
208	Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 549-556.	2.8	26
209	Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. American Heart Journal, 2004, 147, 847-852.	2.7	26
210	Association of a History of Systemic Hypertension With Mortality, Thrombotic, and Bleeding Complications Following Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of Clinical Hypertension, 2006, 8, 315-322.	2.0	26
211	Impact of Time of Presentation on Process Performance and Outcomes in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 656-663.	2.2	26
212	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial. American Heart Journal, 2015, 170, 1140-1150.	2.7	26
213	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€IT PCI. Journal of the American Heart Association, 2022, 11, e022937.	3.7	26
214	Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239Â234 Patients During 2005 to 2018 in the United States. Journal of the American Heart Association, 2022, 11, e022198.	3.7	26
215	Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). American Journal of Cardiology, 2005, 95, 611-614.	1.6	25
216	Niacin at 56 Years of Age — Time for an Early Retirement?. New England Journal of Medicine, 2011, 365, 2318-2320.	27.0	25

#	Article	IF	CITATIONS
217	Achievement of Guideline-Concordant Care and In-Hospital Outcomes in Patients With Coronary Artery Disease in Teaching and Nonteaching Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 58-65.	2.2	25
218	Standard dose versus low dose non–vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. Heart Rhythm, 2016, 13, 2340-2347.	0.7	25
219	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 856-864.	2.9	25
220	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2020, 304, 185-191.	1.7	25
221	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537.	2.8	25
222	Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?. , 1998, 5, 191-202.		24
223	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	1.5	24
224	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. Journal of the American College of Cardiology, 2021, 77, 259-267.	2.8	24
225	Medication Discontinuation in the IMPROVE-IT Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005041.	2.2	23
226	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. JAMA Cardiology, 2020, 5, 787.	6.1	23
227	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. European Heart Journal, 2021, 42, 4821-4829.	2.2	23
228	Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). American Journal of Cardiology, 2000, 85, 1409-1413.	1.6	22
229	Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal, 2013, 166, 723-728.	2.7	22
230	Edoxaban. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 409-416.	2.0	22
231	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA Cardiology, 2017, 2, 556.	6.1	22
232	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation, 2019, 140, 1792-1801.	1.6	22
233	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149.	3.4	22
234	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22

#	Article	IF	CITATIONS
235	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology, 2021, 78, 1499-1507.	2.8	22
236	Heart-Type Fatty Acid Binding Protein as a marker of reperfusion after thrombolytic therapy. Clinica Chimica Acta, 2000, 298, 85-97.	1.1	21
237	The Prognostic Value of Serum Creatinine on Admission in Fibrinolytic-Eligible Patients with Acute Myocardial Infarction. Journal of Thrombosis and Thrombolysis, 2003, 16, 167-174.	2.1	21
238	Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. American Journal of Cardiology, 2003, 92, 595-597.	1.6	21
239	Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. American Journal of Cardiology, 2005, 95, 383-386.	1.6	21
240	Effect of Thrombocytopenia on Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting With Acute Coronary Syndromes. American Journal of Cardiology, 2007, 100, 1734-1738.	1.6	21
241	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGACE AF‶IMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	3.7	21
242	The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. European Heart Journal, 2004, 25, 1139-1145.	2.2	20
243	Usefulness of the TIMI Risk Index in Predicting Short- and Long-Term Mortality in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2005, 96, 773-777.	1.6	20
244	The facts behind niacin. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 227-240.	2.1	20
245	Relation Between Time of Symptom Onset of <scp>ST</scp> â€Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. Clinical Cardiology, 2013, 36, 222-227.	1.8	20
246	Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 97-106.	3.0	19
247	Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. American Heart Journal, 2015, 170, 669-674.	2.7	19
248	First experience with edoxaban and atrial fibrillation ablation – Insights from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2017, 244, 192-195.	1.7	19
249	Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 927-935.	2.9	18
250	Can We Predict Outcomes in Atrial Fibrillation?. Clinical Cardiology, 2012, 35, 10-4.	1.8	18
251	Radial versus femoral access, bleeding and ischemic events in patients with non–ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal, 2013, 165, 583-590.e1.	2.7	18
252	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. International Journal of Cardiology, 2013, 168, 2510-2517.	1.7	18

#	Article	IF	CITATIONS
253	Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice. American Journal of Cardiovascular Drugs, 2014, 14, 111-127.	2.2	18
254	Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 2017, 377, 1996-1997.	27.0	18
255	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2018, 257, 102-107.	1.7	18
256	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2018, 118, 1001-1008.	3.4	18
257	Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF–TIMI 48. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 176-185.	1.0	18
258	Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy). American Journal of Cardiology, 2003, 92, 598-600.	1.6	17
259	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials. Circulation, 2016, 133, 1560-1573.	1.6	17
260	Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era. JAMA Cardiology, 2017, 2, 935.	6.1	17
261	Andexanet Alfa (Andexxa) Formulary Review. Critical Pathways in Cardiology, 2019, 18, 66-71.	0.5	17
262	Prognostic value of SPECT myocardial perfusion imaging in patients with elevated cardiac troponin l levels and atypical clinical presentation. Journal of Nuclear Cardiology, 2007, 14, 53-58.	2.1	16
263	Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiology, 2011, 7, 459-470.	1.2	16
264	Age, treatment, and outcomes in high-risk nonâ€6T-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. International Journal of Cardiology, 2013, 167, 2580-2587.	1.7	16
265	New oral anticoagulants in patients with atrial fibrillation – Authors'reply. Lancet, The, 2014, 384, 25-26.	13.7	16
266	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension, 2019, 74, 597-605.	2.7	16
267	Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. American Journal of Cardiology, 2020, 127, 176-183.	1.6	16
268	What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Cardiology and Therapy, 2020, 9, 59-73.	2.6	16
269	Characteristics and prognosis of patients with suspected acute myocardial infarction and elevated MB relative index but normal total creatine kinase. American Journal of Cardiology, 1999, 84, 957-962.	1.6	15
270	Prognostic Implications of Low Level Cardiac Troponin Elevation Using High‣ensitivity Cardiac Troponin T. Clinical Cardiology, 2015, 38, 230-235.	1.8	15

#	Article	IF	CITATIONS
271	A novel approach indirectly comparing benefit–risk balance across anti-thrombotic therapies in patients with atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 15-28.	3.0	15
272	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). American Heart Journal, 2016, 182, 89-96.	2.7	15
273	2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 114-115.	3.3	14
274	Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. Chronobiology International, 2012, 29, 1390-1396.	2.0	14
275	Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2014, 168, 182-188.e1.	2.7	14
276	The Year in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 201-214.	2.8	14
277	Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Digestive Diseases and Sciences, 2016, 61, 3425-3435.	2.3	14
278	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. American Journal of Medicine, 2016, 129, 1117-1123.e2.	1.5	14
279	Competing Risks of Cardiovascular Versus Noncardiovascular Death During Longâ€Term Followâ€Up After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	14
280	Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. Circulation, 2021, 144, 1732-1734.	1.6	14
281	Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. Journal of the American College of Cardiology, 2005, 45, 357-362.	2.8	13
282	Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. American Heart Journal, 2009, 158, 695-705.	2.7	13
283	Lipid lowering goals: back to nature?. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 185-191.	2.1	13
284	The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2012, 60, 2127-2139.	2.8	13
285	The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology, 2013, 168, 2315-2321.	1.7	13
286	Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 555-559.	2.0	13
287	Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience. Cardiology and Therapy, 2015, 4, 197-201.	2.6	13
288	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48) trial. American Heart Journal, 2016, 172, 144-151.	2.7	13

#	Article	IF	CITATIONS
289	The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 554-561.	1.0	13
290	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58Â634 patients across four randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f40-f49.	3.0	13
291	Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―. Circulation Journal, 2021, 85, 2063-2070.	1.6	13
292	Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina. American Heart Journal, 2000, 139, 867-873.	2.7	12
293	Combination Reperfusion Therapy with Eptifibatide and Tenecteplase for Acute Myocardial Infarction. Cardiology, 2001, 1, 5-13.	0.3	12
294	Anticoagulation After Heart Valve Replacement or Transcatheter Valve Implantation. American Journal of Cardiology, 2016, 118, 1419-1426.	1.6	12
295	Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 167-175.	3.0	12
296	Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. American Journal of Cardiology, 2004, 94, 178-181.	1.6	11
297	Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: Insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology. 2009. 25. e417-e421.	1.7	11
298	Dabigatran. Critical Pathways in Cardiology, 2011, 10, 117-127.	0.5	11
299	In Patients With Acute Myocardial Infarction, the Impact of Hyperglycemia as a Risk Factor for Mortality Is Not Homogeneous Across Age-Groups. Diabetes Care, 2012, 35, 150-152.	8.6	11
300	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non–ST-segment elevation myocardial infarction. American Heart Journal, 2016, 171, 25-32.	2.7	11
301	Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. Value in Health Regional Issues, 2017, 12, 74-83.	1.2	11
302	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal, 2021, 233, 48-58.	2.7	11
303	Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. International Journal of Cardiology, 2012, 155, 424-429.	1.7	10
304	Bridging therapy after recent stent implantation: case report and review of data. Cardiovascular Revascularization Medicine, 2012, 13, 30-38.	0.8	10
305	Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. International Journal of Cardiology, 2013, 167, 548-554.	1.7	10
306	Angiographic Outcomes With Early Eptifibatide Therapy in Non–ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial). American Journal of Cardiology, 2014, 113, 1297-1305.	1.6	10

#	Article	IF	CITATIONS
307	Edoxaban Versus Warfarin in LatinÂAmerican Patients With AtrialÂFibrillation. Journal of the American College of Cardiology, 2018, 72, 1466-1475.	2.8	10
308	Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 423-432.	2.0	10
309	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian) Tj ETQq1 1 0. Outcomes, 2020, 6, 284-292.	784314 rg 4.0	BT /Overlock 10
310	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation, 2021, 143, 673-684.	1.6	10
311	Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011382.	3.9	10
312	The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2008, 52, 1095-1103.	2.8	9
313	One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. European Heart Journal, 2010, 31, 2097-2102.	2.2	9
314	Coronary Artery Stents: Advances in Technology. Hospital Practice (1995), 2014, 42, 83-91.	1.0	9
315	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hematology/Oncology Clinics of North America, 2016, 30, 1019-1034.	2.2	9
316	DOACs in Patients With Mitral Stenosis and Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 1132-1134.	2.8	9
317	Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens. Drugs, 2009, 69, 1433-1443.	10.9	8
318	Dabigatran Excess: Case Report and Review of the Literature. Cardiology and Therapy, 2013, 2, 111-124.	2.6	8
319	Acute Dissection of the Descending Aorta: A Case Report and Review of the Literature. Cardiology and Therapy, 2013, 2, 199-213.	2.6	8
320	Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology. European Heart Journal, 2013, 34, 2031-2033.	2.2	8
321	Genotype-Guided Dosing of Warfarin. Clinical Chemistry, 2014, 60, 920-922.	3.2	8
322	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). American Journal of Cardiology, 2016, 118, 625-631.	1.6	8
323	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. American Journal of Medicine, 2017, 130, 1170-1176.	1.5	8
324	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	8

#	Article	IF	CITATIONS
325	Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: AÂmeta-analysis of randomized controlled trials. Journal of the Formosan Medical Association, 2017, 116, 591-598.	1.7	8
326	Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. European Heart Journal Digital Health, 2022, 3, 38-48.	1.7	8
327	Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator. Journal of Thrombosis and Thrombolysis, 1998, 6, 103-108.	2.1	7
328	Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. American Journal of Cardiology, 2004, 94, 1113-1117.	1.6	7
329	A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. European Heart Journal, 2007, 28, 2070-2076.	2.2	7
330	The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2011, 58, 2342-2354.	2.8	7
331	Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal, 2011, 162, 884-892.e1.	2.7	7
332	Effectiveness and Safety of Percutaneous Coronary Intervention After Fibrinolytic Therapy for ST-Segment Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2011, 107, 1001-1009.	1.6	7
333	Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non–ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. International Journal of Cardiology, 2017, 232, 264-270.	1.7	7
334	Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials. Heart Rhythm, 2017, 14, 599-605.	0.7	7
335	PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. Journal of Clinical Lipidology, 2018, 12, 835-843.	1.5	7
336	The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. Cardiovascular Drugs and Therapy, 2018, 32, 435-442.	2.6	7
337	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. JACC: CardioOncology, 2020, 2, 385-396.	4.0	7
338	Management of <scp>LDL</scp> â€cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. Clinical Cardiology, 2020, 43, 684-690.	1.8	7
339	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation, 2021, 144, 249-251.	1.6	7
340	Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Current Opinion in Lipidology, 2022, 33, 147-159.	2.7	7
341	A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study, Journal of Thrombosis and Thrombolysis, 1998, 5, 49-52.	2.1	6
342	Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 1170-1176.	2.8	6

#	Article	IF	CITATIONS
343	Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. American Heart Journal, 2010, 159, 55-62.	2.7	6
344	Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2019, 48, 217-224.	2.1	6
345	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace, 2019, 21, 306-312.	1.7	6
346	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006511.	2.2	6
347	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	3.6	6
348	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American Heart Journal, 2022, 247, 24-32.	2.7	6
349	Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. European Heart Journal Supplements, 2022, 24, A1-A10.	0.1	6
350	Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. American Journal of Cardiology, 2004, 94, 108-111.	1.6	5
351	Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. American Journal of Cardiology, 2005, 95, 337-342.	1.6	5
352	The Year in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 48, 386-395.	2.8	5
353	When Past Is Prologue. New England Journal of Medicine, 2009, 360, 1016-1022.	27.0	5
354	The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2009, 54, 1544-1555.	2.8	5
355	Practice patterns and clinical outcomes among nonâ€STâ€segment elevation acute coronary syndrome (NSTEâ€ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTEâ€ACS (EARLYâ€ACS) trial. Catheterization and Cardiovascular Interventions, 2014, 84, 934-942.	1.7	5
356	Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. International Journal of Cardiology, 2016, 222, 615-619.	1.7	5
357	Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. International Journal of Cardiology, 2016, 203, 708-713.	1.7	5
358	Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiology, 2021, 6, 582.	6.1	5
359	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Journal of Clinical Neuroscience, 2021, 86, 294-300.	1.5	5
360	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 695-706.	3.0	5

#	Article	IF	CITATIONS
361	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLoS ONE, 2022, 17, e0266615.	2.5	5
362	Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: do the results apply to all patients?. American Journal of Cardiology, 2000, 86, 908-912.	1.6	4
363	Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction. Expert Opinion on Investigational Drugs, 2000, 9, 2689-2694.	4.1	4
364	Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. American Journal of Cardiology, 2005, 95, 228-233.	1.6	4
365	The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. International Journal of Cardiology, 2008, 131, 105-112.	1.7	4
366	Management of ST-Elevation Myocardial Infarction. American Journal of Cardiovascular Drugs, 2008, 8, 187-197.	2.2	4
367	Antiplatelet Therapy in Early Management of Non-ST-segment Elevation Acute Coronary Syndrome: The 2002 and 2007 Guidelines From North America and Europe. Journal of Cardiovascular Pharmacology, 2008, 51, 425-433.	1.9	4
368	ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. Journal of Thrombosis and Thrombolysis, 2009, 27, 1-10.	2.1	4
369	Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. Journal of Interventional Cardiology, 2011, 24, 119-136.	1.2	4
370	Clinical Implications and Correlates of Q Waves in Patients With <scp>ST</scp> â€Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the <scp>CLARITYâ€TIMI</scp> 28 Trial. Clinical Cardiology, 2014, 37, 160-166.	1.8	4
371	Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. Current Opinion in Cardiology, 2016, 31, 644-653.	1.8	4
372	Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 857-864.	1.6	4
373	Cardiovascular Events and Longâ€Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVEâ€IT. Journal of the American Heart Association, 2022, 11, e022733.	3.7	4
374	Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. Journal of Clinical Lipidology, 2022, 16, 538-543.	1.5	4
375	Low-Molecular-Weight Heparins for the Treatment of Acute Coronary Syndromes. Seminars in Vascular Medicine, 2003, 03, 391-402.	2.1	3
376	Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond. Future Cardiology, 2007, 3, 365-375.	1.2	3
377	The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 50, 1386-1395.	2.8	3
378	Antiplatelet Therapy in Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2009, 8, 12-19.	0.5	3

#	Article	IF	CITATIONS
379	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. Current Atherosclerosis Reports, 2013, 15, 290.	4.8	3
380	Cholesterol Levels and the Association of Statins With Inâ€Hospital Mortality of Myocardial Infarction Patients Insights From a Chilean Registry of Myocardial Infarction. Clinical Cardiology, 2013, 36, 305-311.	1.8	3
381	Perioperative Management of Target-Specific Oral Anticoagulants. Hospital Practice (1995), 2014, 42, 38-45.	1.0	3
382	Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. Hospital Practice (1995), 2015, 43, 258-267.	1.0	3
383	Reply. Journal of the American College of Cardiology, 2016, 68, 326.	2.8	3
384	Major Bleeding in Patients With Diabetes and Atrial Fibrillation Treated With New Oral Anticoagulants—Reply. JAMA Cardiology, 2017, 2, 1168.	6.1	3
385	Impact of Antithrombotic Regimen on Mortality, Ischemic, and Bleeding Outcomes after Transcatheter Aortic Valve Replacement. Cardiology and Therapy, 2018, 7, 71-77.	2.6	3
386	Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. Cardiology and Therapy, 2020, 9, 1-4.	2.6	3
387	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. American Heart Journal, 2021, 235, 132-139.	2.7	3
388	Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. American Journal of Cardiology, 2005, 95, 224-227.	1.6	2
389	Treatment Strategies in Nonâ€STâ€Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidenceâ€Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. Journal of Interventional Cardiology, 2008, 21, 283-299.	1.2	2
390	Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 84-99.	0.9	2
391	Left Bundle Branch Block in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2013, 61, 1461-1463.	2.8	2
392	Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non–ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal, 2013, 166, 466-473.e1.	2.7	2
393	The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 526-532.	2.0	2
394	Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2015, 39, 129-138.	2.1	2
395	Antiplatelet and Anticoagulation Treatment in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Cardiology in Review, 2016, 24, 170-176.	1.4	2
396	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. International Journal of Stroke, 2016, 11, 950-967.	5.9	2

#	Article	IF	CITATIONS
397	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 214-220.	3.0	2
398	Clinical benefits of evolocumab appear less than hoped – Authors' reply. Lancet, The, 2018, 391, 934-935.	13.7	2
399	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. International Journal of Cardiology, 2020, 317, 159-166.	1.7	2
400	Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance― Drug Safety, 2021, 44, 503-504.	3.2	2
401	Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Global Cardiology Science & Practice, 2020, 2020, e202039.	0.4	2
402	Relationship of diabetes, heart failure, and Nâ€ŧerminal proâ€Bâ€ŧype natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. ESC Heart Failure, 2022, , .	3.1	2
403	Neural Networks, Logistic Regression, and Calibration: A Reply. Medical Decision Making, 1998, 18, 444-445.	2.4	1
404	Improving antithrombotic treatment in patients after myocardial infarction. Lancet, The, 2003, 362, 757.	13.7	1
405	Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. Future Cardiology, 2006, 2, 85-91.	1.2	1
406	Glycoprotein IIb-IIIa Inhibitors in the Emergency Department for Patients with Non-ST-Elevation Acute Coronary Syndromes: Principles and Practices. Journal of Emergency Medicine, 2009, 36, 162-170.	0.7	1
407	Day 1 care in patients with non-ST-segment elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2010, 11, 41-51.	0.8	1
408	Perspectives on the 2009 Focused Updates on the Management of ST-Segment Elevation Myocardial Infarction and Percutaneous Intervention. Critical Pathways in Cardiology, 2010, 9, 126-133.	0.5	1
409	Management of Non–ST-Segment Elevation Acute Coronary Syndrome. Critical Pathways in Cardiology, 2012, 11, 62-73.	0.5	1
410	Letter from the Editor. Cardiology and Therapy, 2012, 1, 1.	2.6	1
411	Emerging antithrombotic drugs for acute coronary syndrome. Expert Opinion on Emerging Drugs, 2013, 18, 307-318.	2.4	1
412	Cardiac Sarcoidosis: Case Report, Workup, and Review of the Literature. Cardiology and Therapy, 2013, 2, 181-197.	2.6	1
413	Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 199-210.	2.0	1
414	Response to Letter Regarding Article, "Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment Elevation Acute Coronary Syndromes― Circulation, 2013, 127, e634.	1.6	1

#	Article	IF	CITATIONS
415	Do Diabetic Patients with Acute Coronary Syndromes Have a Higher Threshold for Ischemic Pain?. Arquivos Brasileiros De Cardiologia, 2014, 103, 183-91.	0.8	1
416	Target-Specific Oral Anticoagulants: Practice Issues for the Clinician. Hospital Practice (1995), 2014, 42, 48-61.	1.0	1
417	Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants. European Heart Journal, 2014, 35, 207-208.	2.2	1
418	Influence of proven oral therapies in the very old with acute coronary syndromes: A 15year experience. International Journal of Cardiology, 2015, 198, 213-215.	1.7	1
419	Reply. Journal of the American College of Cardiology, 2016, 67, 3025-3026.	2.8	1
420	Reply. Journal of the American College of Cardiology, 2017, 70, 1200.	2.8	1
421	Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease. Expert Opinion on Pharmacotherapy, 2018, 19, 1013-1019.	1.8	1
422	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. Journal of the American College of Cardiology, 2020, 75, 835-837.	2.8	1
423	Reply. Journal of the American College of Cardiology, 2021, 77, 3232-3233.	2.8	1
424	A Targeted Proteomic Approach Identifies Novel Biomarkers ofÂArterial Thromboembolic Risk in ENGAGE AF-TIMI 48. Journal of the American College of Cardiology, 2021, 78, 634-636.	2.8	1
425	Letter to the editor re: â€~serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert Review of Clinical Pharmacology, 2021, 14, 281-282.	3.1	1
426	Abstract 16708: Increasing Age and the Benefit From Higher-intensity Lipid Lowering With Ezetimibe/Simvastatin vs. Simvastatin Alone: Results From the IMPROVE-IT Trial. Circulation, 2015, 132, .	1.6	1
427	Importance of dose selection in novel oral anticoagulants for atrial fibrillation. Archivos De Cardiologia De Mexico, 2012, 82, 308-311.	0.2	1
428	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. Advances in Therapy, 2022, 39, 1832-1843.	2.9	1
429	Prognostic stratification of the patient after myocardial infarction in the thrombolytic era. ACC Current Journal Review, 1995, 4, 36-39.	0.1	0
430	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. Journal of Thrombosis and Thrombolysis, 1997, 4, 321-323.	2.1	0
431	Baseline troponin in acute coronary syndromes managed invasively. American Journal of Medicine, 2004, 117, 963-965.	1.5	0

432 Non ST-Elevation Acute Coronary Syndromes. , 2007, , 221-245.

0

#	Article	IF	CITATIONS
433	ED to catheterization laboratory: a roundtable integrating trials with practice. American Journal of Emergency Medicine, 2011, 29, 1203-1216.	1.6	Ο
434	Adjunctive pharmacologic therapy in percutaneous coronary intervention. Coronary Artery Disease, 2011, 22, 100-112.	0.7	0
435	Adjunctive pharmacologic therapy in percutaneous coronary intervention. Coronary Artery Disease, 2011, 22, 113-121.	0.7	О
436	Relationships Among Race, Bleeding, and Mortality in Coronary Reperfusion. Circulation, 2012, 125, 1715-1717.	1.6	0
437	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18–19, 2012, Belo Horizonte, Minas Gerais, Brazil. Journal of Thrombosis and Thrombolysis, 2013, 36, 115-130.	2.1	Ο
438	Non–ST-Segment Elevation Acute Coronary Syndromes. , 2013, , 153-177.		0
439	Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?. Future Cardiology, 2014, 10, 153-155.	1.2	Ο
440	Editors' Picks for 2014 and a Look into the Future. Cardiology and Therapy, 2015, 4, 1-3.	2.6	0
441	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT― Circulation, 2016, 133, e463.	1.6	0
442	Overview of the non-vitamin K oral anticoagulants for atrial fibrillation. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 77-79.	2.1	0
443	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq1 1 0	.78 43 514 r	gBT¢Overlock
444	Reply. Journal of the American College of Cardiology, 2019, 74, 2436-2437.	2.8	0
445	Cardiology and Therapy: A Summary of 2018 and Key Areas of Emerging Research in 2019. Cardiology and Therapy, 2019, 8, 1-3.	2.6	Ο
446	Correctly understanding the diabetes data in FOURIER. Diabetes, Obesity and Metabolism, 2019, 21, 2342-2343.	4.4	0
447	Interindividual and Intraindividual Responses to PCSK9 Inhibition—Reply. JAMA Cardiology, 2019, 4, 600.	6.1	Ο
448	Association of APOE genotype and lipid lowering with cognitive function in a randomized placeboâ€controlled trial of Evolocumab. Alzheimer's and Dementia, 2020, 16, e047188.	0.8	0
449	Myocardial Infarction and Evolocumab—Reply. JAMA Cardiology, 2021, 6, 1222.	6.1	Ο
450	Assessment of the Change of a Continuous Variable as a Function of its Initial Value—Reply. JAMA Cardiology, 2021, 6, 1342.	6.1	0

#	Article	IF	CITATIONS
451	Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. Fundamental and Clinical Cardiology, 2009, , 19-36.	0.0	0
452	Novel Oral Antiplatelet Agents. European Cardiology Review, 2011, 7, 294.	2.2	0
453	Abstract 14997: Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2020, 142, .	1.6	0
454	Abstract 15091: Significant Reductions in Both Adjudicated and Investigator-Reported Ischemic Events in REDUCE-IT. Circulation, 2020, 142, .	1.6	0
455	Abstract 13200: Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further) Tj ETQq1 1 0.784314 Circulation, 2020, 142.	rgBT /Ovei	lgck 10 Tf 5
456	Reply. Journal of the American College of Cardiology, 2022, 79, e153.	2.8	0